These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

981 related articles for article (PubMed ID: 29094307)

  • 1. Plant-based chimeric HPV-virus-like particles bearing amyloid-β epitopes elicit antibodies able to recognize amyloid plaques in APP-tg mouse and Alzheimer's disease brains.
    Gonzalez-Castro R; Acero Galindo G; García Salcedo Y; Uribe Campero L; Vazquez Perez V; Carrillo-Tripp M; Gevorkian G; Gomez Lim MA
    Inflammopharmacology; 2018 Jun; 26(3):817-827. PubMed ID: 29094307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel monoclonal antibody 3B8 specifically recognizes pyroglutamate-modified amyloid β 3-42 peptide in brain of AD patients and 3xTg-AD transgenic mice.
    Acero G; Garay C; Venegas D; Ortega E; Gevorkian G
    Neurosci Lett; 2020 Apr; 724():134876. PubMed ID: 32114116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-truncated Aβ
    Wirths O; Walter S; Kraus I; Klafki HW; Stazi M; Oberstein TJ; Ghiso J; Wiltfang J; Bayer TA; Weggen S
    Alzheimers Res Ther; 2017 Oct; 9(1):80. PubMed ID: 28978359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42).
    Rockenstein E; Mallory M; Mante M; Sisk A; Masliaha E
    J Neurosci Res; 2001 Nov; 66(4):573-82. PubMed ID: 11746377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Arctic amyloid-β precursor protein (AβPP) mutation results in distinct plaques and accumulation of N- and C-truncated Aβ.
    Philipson O; Lord A; Lalowski M; Soliymani R; Baumann M; Thyberg J; Bogdanovic N; Olofsson T; Tjernberg LO; Ingelsson M; Lannfelt L; Kalimo H; Nilsson LN
    Neurobiol Aging; 2012 May; 33(5):1010.e1-13. PubMed ID: 22118948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active immunization with the peptide epitope vaccine Aβ3-10-KLH induces a Th2-polarized anti-Aβ antibody response and decreases amyloid plaques in APP/PS1 transgenic mice.
    Ding L; Meng Y; Zhang HY; Yin WC; Yan Y; Cao YP
    Neurosci Lett; 2016 Nov; 634():1-6. PubMed ID: 27693663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and beta-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain.
    Bürger S; Noack M; Kirazov LP; Kirazov EP; Naydenov CL; Kouznetsova E; Yafai Y; Schliebs R
    Int J Dev Neurosci; 2009 Oct; 27(6):517-23. PubMed ID: 19589380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques.
    Kalback W; Watson MD; Kokjohn TA; Kuo YM; Weiss N; Luehrs DC; Lopez J; Brune D; Sisodia SS; Staufenbiel M; Emmerling M; Roher AE
    Biochemistry; 2002 Jan; 41(3):922-8. PubMed ID: 11790115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. beta-amyloid deposits in transgenic mice expressing human beta-amyloid precursor protein have the same characteristics as those in Alzheimer's disease.
    Terai K; Iwai A; Kawabata S; Tasaki Y; Watanabe T; Miyata K; Yamaguchi T
    Neuroscience; 2001; 104(2):299-310. PubMed ID: 11377835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice.
    Petrushina I; Ghochikyan A; Mktrichyan M; Mamikonyan G; Movsesyan N; Davtyan H; Patel A; Head E; Cribbs DH; Agadjanyan MG
    J Neurosci; 2007 Nov; 27(46):12721-31. PubMed ID: 18003852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.
    Wirths O; Bethge T; Marcello A; Harmeier A; Jawhar S; Lucassen PJ; Multhaup G; Brody DL; Esparza T; Ingelsson M; Kalimo H; Lannfelt L; Bayer TA
    J Neural Transm (Vienna); 2010 Jan; 117(1):85-96. PubMed ID: 19823761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. K114 inhibits A-beta aggregation and inflammation in vitro and in vivo in AD/Tg mice.
    Zhang YH; Mann D; Raymick J; Sarkar S; Paule MG; Lahiri DK; Dumas M; Bell-Cohen A; Schmued LC
    Curr Alzheimer Res; 2014 Mar; 11(3):299-308. PubMed ID: 24552157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of peptides that specifically bind Abeta1-40 amyloid in vitro and amyloid plaques in Alzheimer's disease brain using phage display.
    Kang CK; Jayasinha V; Martin PT
    Neurobiol Dis; 2003 Oct; 14(1):146-56. PubMed ID: 13678675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic.
    Hook G; Yu J; Toneff T; Kindy M; Hook V
    J Alzheimers Dis; 2014; 41(1):129-49. PubMed ID: 24595198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.
    Rockenstein E; Torrance M; Mante M; Adame A; Paulino A; Rose JB; Crews L; Moessler H; Masliah E
    J Neurosci Res; 2006 May; 83(7):1252-61. PubMed ID: 16511867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesis.
    Crews L; Rockenstein E; Masliah E
    Brain Struct Funct; 2010 Mar; 214(2-3):111-26. PubMed ID: 20091183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial.
    Davtyan H; Ghochikyan A; Petrushina I; Hovakimyan A; Davtyan A; Poghosyan A; Marleau AM; Movsesyan N; Kiyatkin A; Rasool S; Larsen AK; Madsen PJ; Wegener KM; Ditlevsen DK; Cribbs DH; Pedersen LO; Agadjanyan MG
    J Neurosci; 2013 Mar; 33(11):4923-34. PubMed ID: 23486963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.
    Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC
    Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.